Cancer warning for Regranex
Updated labeling for Regranex (becaplermin gel, from Ethicon) now includes a boxed warning explaining an increased rate of mortality secondary to malignancy in patients treated with three or more tubes of Regranex. A post-marketing study showed no overall increase in cancer incidence in Regranex users, however, there was a 5-fold increased risk of cancer mortality in the group exposed to 3 or more tubes of Regranex.
Regranex is a topical recombinant human platelet-derived growth factor indicated as an adjunct to the treatment of lower extremity diabetic neuropathic ulcers.
For more information call (888) REGRANEX or visit www.Regranex.com.